Randomized, optimal dose finding, Phase II Study of triweekly Abraxane in patients with metastatic breast cancer.

Trial Profile

Randomized, optimal dose finding, Phase II Study of triweekly Abraxane in patients with metastatic breast cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms ABROAD
  • Most Recent Events

    • 08 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 01 May 2015 Planned End Date changed from 1 Nov 2018 to 15 Feb 2019 as reported by Hospital Medical Information Network - Japan.
    • 01 May 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top